REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)-- 网页链接{SystImmune, Inc}. (SystImmune), a clinical-stage biotechnology company, and 网页链接{Bristol Myers Squibb} (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive topline results from a pre-specified interim analysis of a Phase III study (BL-B01D1-307) evaluating izal